No profile data available.
Eledon Pharmaceuticals, Inc. (ELDN) is a healthcare company in the organ transfer treatment drugs industry, based in Irvine, United States, with about 33 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$45.62 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $201.53 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Eledon Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$201.53 million as of October 9, 2026.
Listed companies of a similar size in the same industry (organ transfer treatment drugs) include Mesoblast Limited (MESO), Syndax Pharmaceuticals, Inc. (SNDX), Omeros Corporation (OMER), Equillium, Inc. (EQ).